HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.

Abstract
Platinum-based chemotherapy is a primary treatment for patients with advanced non-small cell lung cancer (NSCLC). Considering individual differences, an effective and convenient method is urgently needed to identify the sensitivity of individual patient to platinum based regimen. Genetic variants in DNA repair genes are presumed to represent important determinants of drug efficacy. Our previous studies have demonstrated the involvement of xeroderma pigmentosum group A (XPA) codon23 and xeroderma pigmentosum group D (XPD) codon751 single-nucleotide polymorphisms (SNPs) in clinical response to platinum based chemotherapy in advanced NSCLC patients. Thus, a follow-up study was carried out to investigate the relevance of these genotypes and survival of the cohort (n = 115). The three-dimensional (3-D), polyacrylamide gel-based DNA microarray method was used to assess the genotypes of XPA and XPD in peripheral lymphocytes. Log-rank test revealed that the variant genotypes of XPA23 (A/G+G/G) were associated with significantly longer progression- free survival (PFS) (6.0 m vs. 10.6 m, log-rank P = 0.001) and overall survival (OS) (11.2 m vs. 20.8 m, log-rank P = 0.001). In Cox proportional hazards model, the hazard ratio (HR) for death in patients with G allele was 0.65 (P = 0.049). While no significant differences were observed in PFS or OS according to XPD Lys751Gln genotypes (log-rank P > 0.05). In combination with our previous short-term clinical results, this study further confirmed that by detecting the SNPs in blood cells, XPA A23G polymorphic variants might be a promising biomarker in predicting a favor prognosis of NSCLC patients and be helpful towards designing individualized treatments.
AuthorsHongyan Cheng, Qin Qin, Xinchen Sun, Fan Li, Ning Sun, Lu Cheng, Zuhong Lu, Baoan Chen
JournalTechnology in cancer research & treatment (Technol Cancer Res Treat) Vol. 12 Issue 5 Pg. 473-82 (Oct 2013) ISSN: 1533-0338 [Electronic] United States
PMID23617284 (Publication Type: Journal Article)
Chemical References
  • DNA, Neoplasm
  • Taxoids
  • XPA protein, human
  • Xeroderma Pigmentosum Group A Protein
  • Deoxycytidine
  • Docetaxel
  • Vinblastine
  • Xeroderma Pigmentosum Group D Protein
  • ERCC2 protein, human
  • Paclitaxel
  • Vinorelbine
  • Gemcitabine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
  • DNA, Neoplasm (analysis)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Disease-Free Survival
  • Docetaxel
  • Drug Resistance, Neoplasm (genetics)
  • Female
  • Genotype
  • Humans
  • Lung Neoplasms (drug therapy, genetics)
  • Male
  • Middle Aged
  • Oligonucleotide Array Sequence Analysis (methods)
  • Paclitaxel (administration & dosage)
  • Polymorphism, Single Nucleotide
  • Predictive Value of Tests
  • Prognosis
  • Survival Rate
  • Taxoids (administration & dosage)
  • Vinblastine (administration & dosage, analogs & derivatives)
  • Vinorelbine
  • Xeroderma Pigmentosum Group A Protein (genetics)
  • Xeroderma Pigmentosum Group D Protein (genetics)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: